St. Louis Trust Co Makes New $1.33 Million Investment in Pfizer Inc. $PFE

Posted by George Bondi on May 24th, 2026

St. Louis Trust Co bought a new position in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 53,471 shares of the biopharmaceutical company’s stock, valued at approximately $1,331,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. MQS Management LLC bought a new position in Pfizer during the 4th quarter worth about $384,000. New Millennium Group LLC grew its holdings in Pfizer by 148.2% during the 4th quarter. New Millennium Group LLC now owns 6,544 shares of the biopharmaceutical company’s stock worth $163,000 after acquiring an additional 3,907 shares in the last quarter. Delta Financial Advisors LLC grew its holdings in Pfizer by 4.6% during the 4th quarter. Delta Financial Advisors LLC now owns 24,868 shares of the biopharmaceutical company’s stock worth $619,000 after acquiring an additional 1,104 shares in the last quarter. Cumberland Partners Ltd boosted its holdings in shares of Pfizer by 70.5% in the 4th quarter. Cumberland Partners Ltd now owns 130,570 shares of the biopharmaceutical company’s stock valued at $3,251,000 after buying an additional 53,970 shares in the last quarter. Finally, Nixon Peabody Trust Co. bought a new stake in shares of Pfizer in the 4th quarter valued at about $203,000. 68.36% of the stock is currently owned by institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. HSBC raised their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada restated an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a report on Thursday, February 12th. Finally, Morgan Stanley raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.61.

Read Our Latest Stock Report on Pfizer

Pfizer Stock Down 0.1%

PFE stock opened at $25.92 on Friday. The firm has a 50 day moving average of $26.86 and a 200 day moving average of $26.23. The stock has a market capitalization of $147.72 billion, a PE ratio of 19.79 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 52 week low of $22.88 and a 52 week high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.